Results 11 to 20 of about 384,231 (258)

In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance

Communications Biology, 2021
Lu Shan et al. present a structure-guided approach to engineer a monovalent form of the fragment crystallizable (Fc) region of an IgG4 antibody to adapt multiple versions of half-life extension modifications and bispecific targeting.
Lu Shan, Nydia Van Dyk, Nantaporn Haskins, Kimberly M. Cook, Kim L. Rosenthal, Ronit Mazor, Sonia Dragulin-Otto, Yu Jiang, Herren Wu, William F. Dall’Acqua, Martin J. Borrok, Melissa M. Damschroder, Vaheh Oganesyan   +12 more
doaj   +1 more source

Full speed AHEAD in antibody discovery [PDF]

Nature Chemical Biology, 2021
Current antibody discovery technologies are limited in terms of their efficacy, accessibility, and scalability. The AHEAD system addresses these limitations by presenting an accelerated evolution workflow for antibody engineering that combines autonomous gene diversification with protein display technology.
Paul R. Sargunas, Jamie B. Spangler
openaire   +2 more sources

Discovery of antibodies. [PDF]

BMJ, 1992
Passive immunisation has been used in clinical practice since the end of last century, mainly for prophylaxis. Success of early treatments was marred by anaphylactic reactions and serum sickness because antibodies or antitoxins were not raised in humans.
M B, Llewelyn, R E, Hawkins, S J, Russell   +2 more
openaire   +2 more sources

Cattle-derived knob paratopes grafted onto peripheral loops of the IgG1 Fc region enable the generation of a novel symmetric bispecific antibody format

Frontiers in Immunology, 2023
In this work we present a novel symmetric bispecific antibody format based on engraftments of cattle-derived knob paratopes onto peripheral loops of the IgG1 Fc region.
Desislava Yanakieva, Lena Vollmer, Andreas Evers, Vanessa Siegmund, Paul Arras, Lukas Pekar, Achim Doerner, Bernhard Valldorf, Harald Kolmar, Stefan Zielonka, Stefan Zielonka, Simon Krah   +11 more
doaj   +1 more source

Development of a high yielding expression platform for the introduction of non-natural amino acids in protein sequences

mAbs, 2020
The ability to genetically encode non-natural amino acids (nnAAs) into proteins offers an expanded tool set for protein engineering. nnAAs containing unique functional moieties have enabled the study of post-translational modifications, protein ...
Gargi Roy, Jason Reier, Andrew Garcia, Tom Martin, Megan Rice, Jihong Wang, Meagan Prophet, Ronald Christie, William Dall’Acqua, Sanjeev Ahuja, Michael A Bowen, Marcello Marelli   +11 more
doaj   +1 more source

A library approach for the de novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization

mAbs, 2023
In this study, we generated a novel library approach for high throughput de novo identification of humanized single-domain antibodies following camelid immunization. To achieve this, VHH-derived complementarity-determining regions-3 (CDR3s) obtained from
Paul Arras, Han Byul Yoo, Lukas Pekar, Christian Schröter, Thomas Clarke, Simon Krah, Daniel Klewinghaus, Vanessa Siegmund, Andreas Evers, Stefan Zielonka   +9 more
doaj   +1 more source

A new dawn for monoclonal antibodies against antimicrobial resistant bacteria

Frontiers in Microbiology, 2022
Antimicrobial resistance (AMR) is a quickly advancing threat for human health worldwide and almost 5 million deaths are already attributable to this phenomenon every year.
Marco Troisi, Eleonora Marini, Valentina Abbiento, Samuele Stazzoni, Emanuele Andreano, Rino Rappuoli, Rino Rappuoli   +6 more
doaj   +1 more source

Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees

Nature Communications, 2022
Here, Andreano and Paciello et al. show, at single cell level, the functional and genetic characteristics underlying the Omicron BA.1 and BA.2 cross-protective antibody response in naïve and previously infected COVID-19 vaccinees.
Emanuele Andreano, Ida Paciello, Silvia Marchese, Lorena Donnici, Giulio Pierleoni, Giulia Piccini, Noemi Manganaro, Elisa Pantano, Valentina Abbiento, Piero Pileri, Linda Benincasa, Ginevra Giglioli, Margherita Leonardi, Piet Maes, Concetta De Santi, Claudia Sala, Emanuele Montomoli, Raffaele De Francesco, Rino Rappuoli   +18 more
doaj   +1 more source

High-throughput bactericidal assays for monoclonal antibody screening against antimicrobial resistant Neisseria gonorrhoeae

Frontiers in Microbiology, 2023
Neisseria gonorrhoeae (gonococcus) is an obligate human pathogen and the etiological agent of the sexually transmitted disease gonorrhea. The rapid rise in gonococcal resistance to all currently available antimicrobials has become a significant public ...
Samuele Stazzoni, Marco Troisi, Valentina Abbiento, Valentina Abbiento, Claudia Sala, Emanuele Andreano, Rino Rappuoli, Rino Rappuoli   +7 more
doaj   +1 more source

Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain

FEBS Open Bio, 2022
Dinutuximab (ch14.18) was the first approved monoclonal antibody against the tumor‐associated antigen disialoganglioside GD2. Despite its success in treating neuroblastoma (NB), it triggers a significant amount of neuropathic pain in patients, possibly ...
Xin‐Yuan Liu, Yi‐Li Chen, Guo‐Jian Liu, Xiang‐Nan Deng, Yue Cui, Jie Tan, Xing‐Chen Dong, Hua‐Ying Li, Gan‐Jun Chen, Zhi‐Min Ou, Chun‐He Wang   +10 more
doaj   +1 more source